Home Companies Catalysts Deep Dives
Vimpat lacosamide APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaNeurology
Launch2008-10-29
US LOE2024-11-01
Peak Sales Est$1800M
Formulations[{"id":"vimpat-oral","doses":"50mg, 100mg, 150mg, 200mg","route":"PO","device":"Tablet/oral solution
Companies
UCB (ORIGINATOR)100%
Mechanism: Sodium channel blocker (VGSC)
Expert: Selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and reducing repetitive neuronal firing.
Everyday: Blocks sodium channels in nerve cells to reduce abnormal electrical activity causing seizures.
Targets: ["NAV"]
Revenue History
PeriodRevenue ($M)
2024$1,450M
Q4 2024$340M
Programs (2)
IndicationStageKey StudyRegional Status
Primary generalized tonic-clonic seizuresAPPROVEDEP0061[{"stage":"APPROVED","region":"US","approval_date":"2020-06-23"},{"stage":"APPRO
Focal onset seizuresAPPROVEDSP667, SP754, SP755[{"stage":"APPROVED","region":"US","approval_date":"2008-10-29"},{"stage":"APPRO
Notes
Lacosamide, an anticonvulsant with unique mechanism enhancing slow inactivation of voltage-gated sodium channels for partial-onset seizures. Available in IV and oral formulations; favorable drug interaction profile.
Data from Supabase · Updated 2026-03-24